Acorah Software Products - Accounts Production 15.0.500 false true 31 December 2022 4 April 2022 false 1 January 2023 31 December 2023 31 December 2023 14024267 Dr Andrew Saich Mr Julian Bryson Mr Rupert Haynes iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 14024267 2022-12-31 14024267 2023-12-31 14024267 2023-01-01 2023-12-31 14024267 frs-core:CurrentFinancialInstruments 2023-12-31 14024267 frs-core:SharePremium 2023-12-31 14024267 frs-core:ShareCapital 2023-12-31 14024267 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31 14024267 frs-bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 14024267 frs-bus:AbridgedAccounts 2023-01-01 2023-12-31 14024267 frs-bus:SmallEntities 2023-01-01 2023-12-31 14024267 frs-bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 14024267 frs-bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 14024267 frs-bus:Director1 2023-01-01 2023-12-31 14024267 frs-bus:Director2 2023-01-01 2023-12-31 14024267 frs-bus:Director3 2023-01-01 2023-12-31 14024267 frs-countries:EnglandWales 2023-01-01 2023-12-31 14024267 2022-04-03 14024267 2022-12-31 14024267 2022-04-04 2022-12-31 14024267 frs-core:CurrentFinancialInstruments 2022-12-31 14024267 frs-core:SharePremium 2022-12-31 14024267 frs-core:ShareCapital 2022-12-31 14024267 frs-core:RetainedEarningsAccumulatedLosses 2022-12-31
Registered number: 14024267
Avata Biosciences Holdings Ltd
Unaudited ABRIDGED Financial Statements
For The Year Ended 31 December 2023
Sachdevs
Contents
Page
Balance Sheet 1—2
Notes to the Abridged Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 14024267
31 December 2023 31 December 2022
Notes £ £ £ £
CURRENT ASSETS
Debtors 4 1,880,713 12,251
Cash at bank and in hand 1,102,555 659,681
2,983,268 671,932
Creditors: Amounts Falling Due Within One Year 5 (29,803 ) (327,560 )
NET CURRENT ASSETS (LIABILITIES) 2,953,465 344,372
TOTAL ASSETS LESS CURRENT LIABILITIES 2,953,465 344,372
NET ASSETS 2,953,465 344,372
CAPITAL AND RESERVES
Called up share capital 6 159 127
Share premium account 4,587,522 699,968
Profit and Loss Account (1,634,216 ) (355,723 )
SHAREHOLDERS' FUNDS 2,953,465 344,372
Page 1
Page 2
For the year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
All of the company's members have consented to the preparation of an Abridged Profit and Loss Account for the year end 31 December 2023 in accordance with section 444(2A) of the Companies Act 2006.
On behalf of the board
Dr Andrew Saich
Director
03/09/2024
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Abridged Financial Statements
1. General Information
Avata Biosciences Holdings Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 14024267 . The registered office is 6 Stratton Street, Mayfair, London, W1J 8LD.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.3. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Current tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
2.4. Research and development
Expenditure on research and development is written off in the year in which it is incurred.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 4 (2022: 4)
4 4
4. Debtors
31 December 2023 31 December 2022
£ £
Due within one year
Other debtors 198,234 12,251
Due after more than one year
Amounts owed by participating interests 1,682,479 -
1,880,713 12,251
5. Creditors: Amounts Falling Due Within One Year
31 December 2023 31 December 2022
£ £
Trade creditors 13,223 526
Other loans - 300,203
Other creditors 16,580 1,250
Taxation and social security - 25,581
29,803 327,560
Page 3
Page 4
6. Share Capital
31 December 2023 31 December 2022
£ £
Allotted, Called up and fully paid 159 127
Page 4